Macrolide-Resistant Mycoplasma pneumoniae Infections among Children after COVID-19 Pandemic, Ohio, USA

Mycoplasma pneumoniae infections decreased in Ohio, USA, during the COVID-19 pandemic but reemerged in 2023; >2,000 cases were reported during September 2023­–September 2024. Of 995 M. pneumoniae–positive samples, 24 (2.4%) had mutations for macrolide-resistant M. pneumoniae (MRMp). MRMp rates a...

Full description

Saved in:
Bibliographic Details
Main Authors: Amy L. Leber, Tori Embry, Kathy Everhart, Jeanette Taveras, Sophonie J. Oyeniran, Huanyu Wang
Format: Article
Language:English
Published: Centers for Disease Control and Prevention 2025-03-01
Series:Emerging Infectious Diseases
Subjects:
Online Access:https://wwwnc.cdc.gov/eid/article/31/3/24-1570_article
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849705715831144448
author Amy L. Leber
Tori Embry
Kathy Everhart
Jeanette Taveras
Sophonie J. Oyeniran
Huanyu Wang
author_facet Amy L. Leber
Tori Embry
Kathy Everhart
Jeanette Taveras
Sophonie J. Oyeniran
Huanyu Wang
author_sort Amy L. Leber
collection DOAJ
description Mycoplasma pneumoniae infections decreased in Ohio, USA, during the COVID-19 pandemic but reemerged in 2023; >2,000 cases were reported during September 2023­–September 2024. Of 995 M. pneumoniae–positive samples, 24 (2.4%) had mutations for macrolide-resistant M. pneumoniae (MRMp). MRMp rates are low but increasing. MRMp surveillance is crucial for monitoring antimicrobial resistance.
format Article
id doaj-art-e01d442ae80c431cb8a6e095a13e9e27
institution DOAJ
issn 1080-6040
1080-6059
language English
publishDate 2025-03-01
publisher Centers for Disease Control and Prevention
record_format Article
series Emerging Infectious Diseases
spelling doaj-art-e01d442ae80c431cb8a6e095a13e9e272025-08-20T03:16:24ZengCenters for Disease Control and PreventionEmerging Infectious Diseases1080-60401080-60592025-03-0131355555810.3201/eid3103.241570Macrolide-Resistant Mycoplasma pneumoniae Infections among Children after COVID-19 Pandemic, Ohio, USAAmy L. LeberTori EmbryKathy EverhartJeanette TaverasSophonie J. OyeniranHuanyu Wang Mycoplasma pneumoniae infections decreased in Ohio, USA, during the COVID-19 pandemic but reemerged in 2023; >2,000 cases were reported during September 2023­–September 2024. Of 995 M. pneumoniae–positive samples, 24 (2.4%) had mutations for macrolide-resistant M. pneumoniae (MRMp). MRMp rates are low but increasing. MRMp surveillance is crucial for monitoring antimicrobial resistance. https://wwwnc.cdc.gov/eid/article/31/3/24-1570_articleMycoplasma pneumoniaeCOVID-19respiratory infectionssevere acute respiratory syndrome coronavirus 2SARS-CoV-2SARS
spellingShingle Amy L. Leber
Tori Embry
Kathy Everhart
Jeanette Taveras
Sophonie J. Oyeniran
Huanyu Wang
Macrolide-Resistant Mycoplasma pneumoniae Infections among Children after COVID-19 Pandemic, Ohio, USA
Emerging Infectious Diseases
Mycoplasma pneumoniae
COVID-19
respiratory infections
severe acute respiratory syndrome coronavirus 2
SARS-CoV-2
SARS
title Macrolide-Resistant Mycoplasma pneumoniae Infections among Children after COVID-19 Pandemic, Ohio, USA
title_full Macrolide-Resistant Mycoplasma pneumoniae Infections among Children after COVID-19 Pandemic, Ohio, USA
title_fullStr Macrolide-Resistant Mycoplasma pneumoniae Infections among Children after COVID-19 Pandemic, Ohio, USA
title_full_unstemmed Macrolide-Resistant Mycoplasma pneumoniae Infections among Children after COVID-19 Pandemic, Ohio, USA
title_short Macrolide-Resistant Mycoplasma pneumoniae Infections among Children after COVID-19 Pandemic, Ohio, USA
title_sort macrolide resistant mycoplasma pneumoniae infections among children after covid 19 pandemic ohio usa
topic Mycoplasma pneumoniae
COVID-19
respiratory infections
severe acute respiratory syndrome coronavirus 2
SARS-CoV-2
SARS
url https://wwwnc.cdc.gov/eid/article/31/3/24-1570_article
work_keys_str_mv AT amylleber macrolideresistantmycoplasmapneumoniaeinfectionsamongchildrenaftercovid19pandemicohiousa
AT toriembry macrolideresistantmycoplasmapneumoniaeinfectionsamongchildrenaftercovid19pandemicohiousa
AT kathyeverhart macrolideresistantmycoplasmapneumoniaeinfectionsamongchildrenaftercovid19pandemicohiousa
AT jeanettetaveras macrolideresistantmycoplasmapneumoniaeinfectionsamongchildrenaftercovid19pandemicohiousa
AT sophoniejoyeniran macrolideresistantmycoplasmapneumoniaeinfectionsamongchildrenaftercovid19pandemicohiousa
AT huanyuwang macrolideresistantmycoplasmapneumoniaeinfectionsamongchildrenaftercovid19pandemicohiousa